Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Lumos Pharma
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:collaboratedWith |
gptkb:Merck_&_Co.
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:developedBy |
HyperAcute immunotherapy platform
|
| gptkbp:focusesOn |
infectious diseases
immunotherapy |
| gptkbp:founded |
1999
|
| gptkbp:founder |
Charles Link
|
| gptkbp:headquartersLocation |
gptkb:Ames,_Iowa,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NewLink Genetics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:keyPerson |
Charles Link
Nicholas N. Vahanian |
| gptkbp:notableProduct |
Ebola vaccine candidate
|
| gptkbp:tradedOn |
NASDAQ: NLNK
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.newlinkgenetics.com/
|
| gptkbp:bfsParent |
gptkb:indoximod
|
| gptkbp:bfsLayer |
8
|